Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) is pleased to announce that Canada’s Drug Agency (CDA) has issued a positive reimbursement recommendation with conditions for PrEMPAVELI® (pegcetacoplan) for the treatment of adult […]